Convert First Digital USD FDUSD to VitaFOXO VITAFOXO

What is the project about? First Digital USD (FDUSD) aim to revolutionize the digital asset landscape. Our mission is to empower users with a transformative financial instrument that combines the stability of cash reserves with the seamless efficiency of advanced blockchain technology. By offering a fully collateralized digital asset, our stablecoin ensures the utmost security, transparency, and transaction reliability. This strategic fusion of traditional stability and cutting-edge innovation allows users to confidently navigate the digital economy, unlocking a world of possibilities while maintaining the utmost trust in their financial interactions. What makes your project unique? Transferable: FDUSD enables frictionless and streamlined transactions, rendering it a convenient choice for a wide range of applications and scenarios. Redeemable: FDUSD is backed by high-quality reserves- cash and cash equivalents, which enable holders the ability to redeem their FDUSD tokens for their equivalent value in US dollars. Users can trust that FDUSD is always 1:1 backed. Low Fees: One notable benefit of FDUSD is its ability to offer cost-effective transactions with minimal fees. Unlike traditional financial transactions, this cost-efficiency makes FDUSD an attractive and economical choice for users. Operates on Decentralized Networks. FDUSD operates on decentralized networks that are distributed across multiple nodes. In so doing, it enhances transparency, security, and resilience. Bankruptcy Remote FDUSD is designed to be bankruptcy remote, with the reserves held in segregated accounts on a registered trust company, separated from the issuer’s operational accounts. It ensures the stablecoin remains stable and secure. History of your project. Established in 2019, First Digital is Asia’s leading multi-faceted trust partner bridging the gap between the traditional and digital financial worlds.

This project will design a new RNA therapeutic that nudges the longevity-linked FOXO3 gene into its health-promoting form to halt the tissue breakdown behind degenerative disc disease—opening a precise, scalable route to drugs that extend healthspan. Dr. Lorna Harries’ lab has identified an innovative way to modulate FOXO3, a well known and yet undrugged longevity target, and propose leveraging it to address chronic lower back pain stemming from degenerative disc disease. They plan to make short, lab-made modified RNA molecules (antisense oligonucleotides) that selectively switch FOXO3’s “good” message on, first in human cells and mini-disc models. Success would yield 1) a lead drug candidate, 2) proof it can restore disc health, and 3) the data needed for patenting and further development. The same molecules could later be adapted to treat many other age-related conditions, helping people stay healthy for longer.